Welcome to our dedicated page for FENNEC PHARMACEUTICALS SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
FENNEC PHARMACEUTICALS INC. reported that former director Rosty Raykov acquired 2,778 common shares on 2026-07-31 in a transaction coded as a grant or award. The shares represent stock released from restriction from an award granted on 5/16/2024, bringing his direct holdings to 141,633 common shares.
FENNEC PHARMACEUTICALS INC. reported that Chief Financial Officer Robert Andrade acquired 1,703 common shares on July 31, 2026 via a grant/award at a stated price of $0.0000 per share. A footnote explains these shares were released from restrictions on awards granted May 16, 2024 and March 28, 2025. After this release, Andrade directly holds 292,675 common shares.
FENNEC PHARMACEUTICALS INC. former director Rosty Raykov reported several equity transactions in common shares. He exercised stock options to acquire 15,597 shares at $2.45 per share and received 2,778 additional shares released from prior restricted awards. On the same date, he sold 9,599 shares at $10.41 per share to satisfy tax obligations, with these actions carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 19, 2025. After these transactions, he directly holds 138,855 common shares.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans reported an equity compensation transaction involving the company’s common shares. On the reported date, Evans acquired 168 common shares through a grant, award, or other acquisition, with no cash price shown for the shares.
Following this award, Evans directly holds 21,183 common shares. A footnote explains that the 168 shares represent shares released from restriction from an award originally granted on March 28, 2025, indicating this is part of a previously approved compensation arrangement rather than an open‑market trade.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad reported a compensation-related stock transaction. He acquired 168 Common Shares at $0.00 per share as a grant or award, representing shares released from restriction on an award originally granted on March 28, 2025. Following this vesting event, he directly holds 21,183 Common Shares. This is a routine equity compensation release rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman reported a compensation-related share acquisition. On June 30, 2026, he received 1,159 Common Shares at no purchase price, reflecting shares released from restriction from an award granted on March 28, 2025. Following this release, he directly owns 63,984 Common Shares. This filing records a routine equity award release rather than an open-market trade.
FENNEC PHARMACEUTICALS INC. Chief Financial Officer Robert Andrade reported a compensation-related share event. He acquired 1,703 common shares at a price of $0.00 per share through a grant/award acquisition, representing shares released from restrictions on prior awards. Following this release, he directly holds 290,972 common shares.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported a routine equity compensation event. She acquired 156 common shares at no cost in a grant or award transaction, bringing her direct holdings to 24,332 common shares. The shares represent a release from restrictions on stock previously awarded on March 28, 2025.
FILER: Notice under Rule 144 on proposed sale of Common stock associated with a stock option exercise.
The entry shows a planned sale dated 07/01/2026 for Common shares tied to a Stock Option Exercise with an entry of 9,599. Prior dispositions by Rostislav Raykov are listed for 06/01/2026 (9,747; proceeds $93,813.90) and 05/01/2026 (10,781; proceeds $69,761.69).
FENNEC PHARMACEUTICALS INC. director Marco Maria Brughera received a grant of stock options as part of his compensation. On June 10, 2026, he was awarded a non-qualified option to purchase 20,000 common shares at an exercise price of $8.70 per share, fully vested on the grant date. Following this grant, his reported option holdings increased to 235,545 derivative securities, indicating this is a routine equity incentive award rather than an open-market purchase or sale.